In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC).
Feeling depressed and lethargic are common side effects of prostate cancer (PCa) and its treatments. We examined the incidence and severity of feeling depressed and lack of energy in patients in a population based PCa registry.
Solitary colorectal metastasis of prostate cancer is very rare, but the pathological features can closely resemble a primary colorectal cancer with poorly differentiated adenocarcinoma. Thus, metastasis of prostate cancer should be considered as a differential diagnosis in male patients with colorectal lesion with poorly differentiated adenocarcinoma.
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston. I’m so excited to have here with me today, a good friend and colleague, Dr. Michael Morris, who’s the Clinical Director of the GU Medical Oncology Service and the Prostate Cancer Section Head at Memorial Sloan […]
Alicia Morgans: Hi, my name is Alicia Morgans, and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston in the U.S. I’m so excited to have here with me today Dr. Richard Cathomas, who is a Medical Oncologist in Chur, Switzerland, where he’s also the Deputy Head Physician at Kantonsspital there. Thank you […]
Over the years, several minimally invasive surgical treatments (MISTs) have been proposed as alternative therapies for benign prostate hyperplasia (BPH) to allow a significant improvement in lower urinary tract symptoms (LUTS) and a reduction in hospital stay and postoperative complications compared to traditional surgery.
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana Farber Cancer Institute. I am so excited to have here with me today a great friend and colleague, Dr. Neeraj Agarwal, who is a Professor of Medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I am so excited to have here with me today a good friend and colleague, Dr. Neeraj Agarwal, who is a Professor of Medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute. […]
To highlight and review the application of artificial intelligence (AI) in kidney stone disease (KSD) for diagnostics, predicting procedural outcomes, stone passage, and recurrence rates. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.
The prevalence of kidney stones is rising and historically carries a preponderance for males. However, recent evidence has questioned whether this gender gap is closing. The aim of this systematic review was to examine this further as well as evaluate possible underlying causes.
